Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Almirall, S.A.”

71 pharma patents match "Almirall, S.A." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 71
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 71 pharmaceutical patents matching "Almirall, S.A." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

71 results for “Almirall, S.A.” · 30,257 patents in full index Clear search

  1. US 11602515

    Pharmaceutical compositions comprising dimethyl fumarate

    Almirall, S.A. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  2. US 11000517

    Dosage and formulation

    Almirall, S.A. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  3. US 10759793

    2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors

    Almirall, S.A. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  4. US 10588895

    Quinuclidine derivatives and medicinal compositions containing the same

    Almirall, S.A. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  5. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Almirall, S.A. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  6. US 10300072

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  7. US 10214509

    Amino-substituted heterocyclic derivatives as sodium channel inhibitors

    Almirall, S.A. · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  8. US 10173985

    Aminoindazole derivatives as sodium channel inhibitors

    Almirall, S.A. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  9. US 10085974

    Dosage and formulation

    Almirall, S.A. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  10. US 10034867

    Quinuclidine derivatives and medicinal compositions containing the same

    Almirall, S.A. · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted
  11. US 10005771

    Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted
  12. US 9907807

    Topical pharmaceutical compositions

    Almirall, S.A. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  13. US 9757383

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  14. US 9737520

    Aclidinium for use in improving the quality of sleep in respiratory patients

    Almirall, S.A. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  15. US 9687478

    Quinuclidine derivatives and medicinal compositions containing the same

    Almirall, S.A. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted
  16. US 9643961

    Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted May 9, 2017 · Expires May 4, 2037

    granted
  17. US 9579316

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities

    Almirall, S.A. · Granted Feb 28, 2017 · Expires Feb 23, 2037

    granted
  18. US 9562039

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

    Almirall, S.A. · Granted Feb 7, 2017 · Expires Feb 2, 2037

    granted
  19. US 9549934

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted
  20. US 9518050

    Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity

    Almirall, S.A. · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted
  21. US 9388189

    Pyrrolotriazinone derivatives as PI3K inhibitors

    Almirall, S.A. · Granted Jul 12, 2016 · Expires Jul 7, 2036

    granted
  22. US 9346759

    Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor

    Almirall, S.A. · Granted May 24, 2016 · Expires May 19, 2036

    granted
  23. US 9340547

    Pyrrolotriazinone derivatives as inhibitors P13K

    Almirall, S.A. · Granted May 17, 2016 · Expires May 12, 2036

    granted
  24. US 9333195

    Quinuclidine derivatives and medicinal compositions containing the same

    Almirall, S.A. · Granted May 10, 2016 · Expires May 5, 2036

    granted